AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33783516
Drug: Shortened duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened duration of adjuvant chemotherapy (3 to 5 months) with FOLFOX (5-fluorouracil/leucovorin plus oxaliplatin)
Trial: 33210651
Drug: Essential drugs
RxNorm normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential drugs prescribed
Trial: 33210651
Drug: Medicines prescribed
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medicines prescribed in generic names
Trial: 33210651
Drug: Adequate response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adequate response on medicine use
Trial: 36226787
Drug: Patient-directed arm
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-directed arm (0-30 tablets of oxycodone 5 mg)
Trial: 36226787
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (30 tablets of oxycodone 5 mg)
Trial: 35035944
Drug: SNF472 (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNF472 (7 mg/kg intravenously) three times weekly for 12 weeks
Trial: 35035944
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times weekly for 12 weeks
Trial: 33595213
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone calls by a clinical dietitian for 3 months
Trial: 33955190
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus intensity-modulated radiotherapy (IC+RT)
Trial: 33955190
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy plus IMRT (CCRT)
Trial: 32579549
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing 2.6g of amino acids and 250 mcg of chromium picolinate
Trial: 34006256
Drug: Neural network
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neural network models using 12 sequential fever data for predicting RMPP-5
Trial: 32873500
Drug: Sublingual buprenorphine–naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine–naloxone
Trial: 33801665
Drug: Beetroot Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot Juice (BJ) 140 mL (12.8 mmol NO3−)
Trial: 32405071
Drug: Continued ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued ACEI/ARB treatment
Trial: 32405071
Drug: Temporary discontinuation
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary discontinuation of ACEI/ARB treatment for 30 days
Trial: 32955913
Drug: Triphala (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphala (2,000 mg daily for 4 weeks)
Trial: 32955913
Drug: Manjistha (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manjistha (2,000 mg daily for 4 weeks)
Trial: 32955913
Drug: Placebo (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2,000 mg daily for 4 weeks)
Trial: 34610941
Drug: HABIT-ILE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HABIT-ILE therapy
Trial: 34610941
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity conventional therapy
Trial: 32459653
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders, feedback, and gain-framed nominal financial incentives (Arm 1)
Trial: 32459653
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message reminders and feedback only (Arm 2)
Trial: 33111581
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran (30 g/day) plus navy bean (30 g/day)
Trial: 33111581
Drug: Fibersol‐2® (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibersol‐2® (10 g/day)
Trial: 36365080
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional laser-assisted delivery of methotrexate (AFL+MTX) therapy
Trial: 36365080
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional laser (AFL) therapy
Trial: 35613766
Drug: Statins alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors
Trial: 33939245
Drug: 400 mcg
RxNorm normalized name: Biotin 400 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mcg of budesonide daily for 3 months
Trial: 35513132
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy (XT)
Trial: 33141635
Drug: Yellow passion
RxNorm normalized name: PASSION FLOWER
DrugBank: Passiflora incarnata flower (DB13974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow passion fruit albedo flour (FAMA) 500 mg capsules, three times a day
Trial: 33141635
Drug: Long turmeric
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long turmeric capsules (CURPI) 500 mg merged with piperine (5 mg)
Trial: 33141635
Drug: Placebo of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of carboxymethyl cellulose (500 mg)
Trial: 35617704
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Lactobacillus rhamnosus GG; L.GG)
Trial: 33034421
Drug: Nuvaring® vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuvaring® vs Injection
Trial: 33034421
Drug: Injection vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection vs Nuvaring®
Trial: 33034421
Drug: Injection vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection vs COC
Trial: 32485993
Drug: 430 mg
RxNorm normalized name: urea 430 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 430 mg green oat extract
Trial: 32485993
Drug: 1290 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1290 mg green oat extract
Trial: 32485993
Drug: 1290 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1290 mg green oat extract (after four weeks)
Trial: 32485993
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1290 mg green oat extract
Trial: 32485993
Drug: Four weeks
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weeks of supplementation with 430 mg and 1290 mg green oat extract
Trial: 33552234
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU subcutaneous growth hormone (GH) administered every other day for 3 months
Trial: 33552234
Drug: 5 IU
RxNorm normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 IU subcutaneous growth hormone (GH)
Trial: 35763704
Drug: Atezolizumab with
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Trial: 35763704
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and pertuzumab-trastuzumab (PH)
Trial: 35763704
Drug: Atezolizumab with
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Trial: 35763704
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel and PH
Trial: 34480632
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline administration
Trial: 33872801
Drug: Responsive preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responsive preventive intervention including point of care testing for early infant HIV diagnosis and maternal viral load, and infant single-drug Pre-Exposure Prophylaxis (lamivudine) if mothers are virally unsuppressed.
Trial: 36241476
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (MG+)
Trial: 36241476
Drug: No magnesium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No magnesium supplementation (MG−)
Trial: 34684517
Drug: MNPs containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNPs containing 10 mg of zinc
Trial: 34684517
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet containing 10 mg zinc
Trial: 34812472
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional physical therapy)
Trial: 36098519
Drug: Ensitrelvir 125
RxNorm normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 125 mg
Trial: 36098519
Drug: Ensitrelvir 250
RxNorm normalized name: ensitrelvir
DrugBank: Ensitrelvir (DB18834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensitrelvir 250 mg
Trial: 32710741
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein intake (>2.1 g · kg LBM‐1 · d‐1)
Trial: 32710741
Drug: Recommended protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended protein intake (1.1 g · kg LBM‐1 · d‐1)
Trial: 35473809
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC) prophylaxis
Trial: 36121686
Drug: Cash transfer
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cash transfer along with combination HIV prevention (CHP) interventions
Trial: 34044875
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg neflamapimod, orally twice daily for 24 weeks
Trial: 32085394
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor (dapagliflozin: up to 10 mg/day)
Trial: 35691282
Drug: 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μg per day of N-Acetyl-Cysteine (NAC) for 12 weeks
Trial: 35691282
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of Selenium (Se) per day for 12 weeks
Trial: 35691282
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of Selenium (Se) and 600 μg of NAC per day for 12 weeks
Trial: 32050222
Drug: Intracameral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral moxifloxacin 500 μg
Trial: 32050222
Drug: Intracameral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral moxifloxacin 250 μg
Trial: 34162484
Drug: Ferric derisomaltose
RxNorm normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric derisomaltose (FDI) 1,000 mg
Trial: 34162484
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (IS) 200 mg (up to 5 doses, recommended cumulative dose 1,000 mg)
Trial: 32102472
Drug: Karaoke training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karaoke training (once a week for two hours, with an hour of homework assigned weekly)
Trial: 35933083
Drug: δ‐tocotrienol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: δ‐tocotrienol 300 mg twice daily for 48 weeks
Trial: 35933083
Drug: α‐tocopherol 268
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α‐tocopherol 268 mg twice daily for 48 weeks
Trial: 32029499
Drug: 2.8 mg
RxNorm normalized name: pectin 2.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 mg folic acid with 60 mg iron weekly for 16 weeks
Trial: 32029499
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg folic acid with 60 mg iron weekly for 16 weeks
Trial: 32029499
Drug: 0.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg (placebo) folic acid with 60 mg iron weekly for 16 weeks
Trial: 32074418
Drug: Nemolizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (0.5 mg/kg, subcutaneously at baseline, week 4, and week 8)
Trial: 34582636
Drug: Unani formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unani formulation
Trial: 33649972
Drug: 2-week spa
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week spa therapy with low-dose radon therapy
Trial: 33649972
Drug: 2-week spa
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week spa therapy without radon therapy
Trial: 33649972
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (with and without radon therapy)
Trial: 36280642
Drug: Crofelemer 125
RxNorm normalized name: crofelemer 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crofelemer 125 mg orally twice daily during chemotherapy cycles 1 and 2
Trial: 36280642
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no scheduled prophylactic medication)
Trial: 32934365
Drug: Novel anticancer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel anticancer agents and combination therapies
Trial: 32934365
Drug: Single-agent or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent or combination therapies
Trial: 32934365
Drug: Multiple agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple agents in a head-to-head comparison
Trial: 32037096
Drug: Sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual (SL) administration of edaravone 60 mg
Trial: 32037096
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion of edaravone 60 mg
Trial: 33058438
Drug: Phenytoin (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (4-6 mg/kg/day)
Trial: 32487575
Drug: Low-dose prescribing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prescribing and environment-friendly drug profiles
Trial: 33176887
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus bevacizumab (10 mg/kg each i.v.)
Trial: 616805373
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal manipulative therapy
Trial: 35556386
Drug: Resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (500 mg/daily for 6 weeks)
Trial: 32869813
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (one of the four test breakfasts)
Trial: 33506447
Drug: Steroids (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (cumulative 4-5 g) + orbital irradiation
Trial: 33506447
Drug: Teprotumumab (IGF-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (IGF-1 receptor antibody)
Trial: 35238041
Drug: NSPT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSPT with 1% melatonin gel
Trial: 35238041
Drug: NSPT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSPT with placebo gel
Trial: 34121140
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg/day for 1 week, then 6 mg/day for 7 weeks)
Trial: 32208439
Drug: Bisoprolol (beta-blocker)
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bisoprolol (beta-blocker)
Trial: 32208439
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor antagonist
Trial: 33370571
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (2000 mg)
Trial: 33067293
Drug: Happy House
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Happy House intervention (six weekly 90 min school-based group sessions)
Trial: 32769877
Drug: Oral probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotics (3 months duration)
Trial: 32769877
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise therapy (control group)
Trial: 32161056
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment for breast cancer
Trial: 32161056
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors treatment for breast cancer
Trial: 32770730
Drug: AZD4831 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 15 mg
Trial: 32770730
Drug: AZD4831 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4831 45 mg
Trial: 32546973
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg alone once daily for seven days (Period I)
Trial: 32546973
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg with linagliptin 20 mg for seven days (Period II)
Trial: 32546973
Drug: Linagliptin 20
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 20 mg alone once daily for seven days (Period I)
Trial: 32546973
Drug: Linagliptin 20
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Linagliptin 20 mg with fimasartan 120 mg for seven days (Period II)
Trial: 33290915
Drug: SLIT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLIT plus pharmacotherapy
Trial: 32925028
Drug: Antipsychotic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medication for agitation related to dementia
Trial: 35344191
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide 1 mg
Trial: 35344191
Drug: Once-daily canagliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily canagliflozin 300 mg
Trial: 33211508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of malleable mindset and social norms
Trial: 34030219
Drug: Acupressure at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure at the p6 point for 10 minutes in both hands, twice a day for two consecutive days.
Trial: 32705703
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (iCBT) with minimal support
Trial: 34330457
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (1 g/day) for 12 weeks
Trial: 32375747
Drug: Regular, low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular, low-dose (≤32 mg/day), sustained-release morphine for chronic breathlessness associated with COPD
Trial: 35347300
Drug: Daily tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tadalafil plus early low-intensity shock wave therapy (LI-SWT)
Trial: 35347300
Drug: Daily tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tadalafil only
Trial: 32320842
Drug: Early intensive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intensive treatment approach using one of four monoclonal antibodies as initial therapy.
Trial: 32320842
Drug: Escalation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalation treatment approach using any other approved medication as initial therapy with subsequent escalation to higher efficacy treatments.
Trial: 35960897
Drug: Conventional Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Radiation Therapy (CRT)